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Abstract
Background: We have previously developed an oncolytic serotype 5 adenovirus (Ad5) with chromogranin-A (CgA)
promoter-controlled E1A expression, Ad[CgA-E1A], with the intention to treat neuroendocrine tumors, including carcinoids.
Since carcinoids tend to metastasize to the liver it is important to fully repress viral replication in hepatocytes to avoid
adenovirus-related liver toxicity. Herein, we explore miRNA-based regulation of E1A expression as a complementary
mechanism to promoter-based transcriptional control.
Methodology/Principal Findings: Ad[CgA-E1A-miR122], where E1A expression is further controlled by six tandem repeats
of the target sequence for the liver-specific miR122, was constructed and compared to Ad[CgA-E1A]. We observed E1A
suppression and replication arrest of the miR122-detargeted adenovirus in normal hepatocytes, while the two viruses killed
carcinoid cells to the same degree. Repeated intravenous injections of Ad[CgA-E1A] induced liver toxicity in mice while
Ad[CgA-E1A-miR122] injections did not. Furthermore, a miR122-detargeted adenovirus with the wild-type E1A promoter
showed reduced replication in hepatic cells compared to wild-type Ad5 but not to the same extent as the miR122-
detargeted adenovirus with the neuroendocrine-selective CgA promoter.
Conclusions/Significance: A combination of transcriptional (promoter) and post-transcriptional (miRNA target) regulation
to control virus replication may allow for the use of higher doses of adenovirus for efficient tumors treatment without liver
toxicity.
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Introduction
Virotherapy is an emerging approach to treat cancer. It utilizes
genetically engineered viruses for selective infection and killing of
tumor cells while leaving normal cells relatively unharmed. Today,
transcriptional and transductional targeting are the two main
strategies to selectively restrict adenovirus activity to tumor cells.
Transcriptional targeting is mainly achieved by replacing an
endogenous viral promoter sequence, e.g., the adenovirus E1A
promoter, with a mammalian tumor- or tissue-specific promoter
[1,2]. This strategy restricts virus replication to target cells where
the promoter is active. Transductional targeting concerns genetic
or chemical alteration of capsid proteins for selective infection of
tumor cells [1,2]. Recently, a novel strategy based on the gene
silencing mechanisms utilized by endogenous microRNAs (miR-
NAs) has been exploited to control viral replication. miRNAs are
small, noncoding RNA molecules 20–24 bp in length that bind to
mRNA in a sequence-specific manner. Partial complementarity in
base-pairing between miRNA and target mRNA can act to
suppress mRNA translation, but upon high sequence homology,
miRNA cause catalytic degradation of target mRNA [3,4,5].
Naldini and colleagues were the first to use miRNA target (miRT)
sequences to specifically suppress transgene expression from
lentiviral vectors in hematopoetic cells or hepatocytes [6,7]. Kelly
et al were able to restrict replication of an oncolytic coxsackievirus
(CVA21) by incorporation of miRT sequences recognized by a
muscle-specific miRNA. This reduced replication of the CVA21
virus in normal muscle tissue and resulted in reduced muscle
toxicity without compromising the tumor cell-killing ability [8].
Two recent publications have described miR122-detargeting of
the human serotype 5 adenovirus (Ad5) to reduce adenovirus-
induced liver toxicity [9,10]. Both publications use the wildtype
E1A promoter to control E1A and demonstrated that incorpora-
tion of miR122 target sequences in the 39UTR of E1A gene
reduces E1A expression in hepatic cells. Quantification of
adenoviral replication was not examined in these papers.
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chromogranin-A (CgA) promoter controls expression of the
adenoviral E1A gene, Ad[CgA-E1A] [11]. CgA is a protein in
secretory granules of neuroendoocrine cells that serves as a
precursor of several biologically active peptides. The CgA gene is
highly expressed in neuroendocrine tumors and CgA is known to
be a sensitive and specific tumor maker for neuroendocrine tumors
[12,13,14]. We demonstrated that the CgA promoter is functional
when inserted in an adenovirus genome and retains selectivity for
neuroendocrine cells, including neuroblastomas and neuroendo-
crine tumors of the ileum, also known as midgut carcinoids [11].
However, despite the fact that CgA is not expressed in the normal
liver cells, Ad[CgA-E1A] shows weak activity in freshly isolated
hepatocytes [11]. Since liver toxicity is potentially the most serious
adverse event of adenovirus-based therapy, we have been
investigating means to reduce Ad[CgA-E1A] activity in hepato-
cytes. In this study, we present further modification of Ad[CgA-
E1A], by introducing miRT sequences for the liver-specific
miR122 in the 39UTR of E1A to down-regulate E1A expression
and thereby viral replication in hepatocytes. To our knowledge
this is the first study to demonstrate that a combination of
transcriptional (promoter) and post-transcriptional (miRNA target)
regulation to control adenovirus replication leads to tighter control
than either of the two regulatory mechanisms alone.
Results
Liver-Specific Expression of miR122
miR122 is specifically expressed in hepatocytes and it is the
most abundant miRNA molecule expressed in the adult liver
where it makes up 70% of all miRNAs [15]. High and specific
miR122 expression was confirmed in normal human liver, Balb/c
mice liver and in the hepatoma cell line HuH7.5 (Supporting
Figure S1). The miR122 expression level was approximately 7-fold
higher in human hepatocytes than in HuH7.5, while miR122 was
not expressed in the hepatoma cell line HepG2 or in the non-
hepatic neuroendocrine tumor cells lines BON (pancreatic
carcinoid), SH-SY-5Y, SK-N-BE(2), Kelly (all neuroblastomas)
or in primary carcinoid cells (Supporting Figure S1). miRNA
studies have shown that the strand used for recognition of target
mRNA is the one, whose 59 end is less tightly paired [16]. Based
on our results and those studies, we designed a target sequence
with six tandem repeats with perfect complementarity to the
mature strand of the miR122 duplex.
A Recombinant Adenoviral Vector with miR122 Target
Sequences Shows Markedly Reduced Activity in Human
Hepatocytes In Vitro and Mouse Liver In Vivo
We constructed two serotype 5 adenoviral vectors with CgA
promoter-controlled luciferase expression with or without miR122
target sequences in the 39UTR of luciferase as presented in
Figure 1. Transduction of freshly isolated hepatocytes with
Ad[CgA-Luc-miR122] demonstrated more than 99% reduction
of luciferase activity, compared to Ad[CgA-Luc] while no
reduction was observed in freshly isolated carcinoid cells
(Figure 2A). Luciferase expression was reduced by approximately
80% in the miR122-positive hepatoma cell line HuH7.5, while no
reduction was observed in the miR122-negative hepatoma cell line
HepG2 (Figure 2A), which strongly indicates miR122-specific
silencing. The raw data on luciferase expression levels in the
primary cells and cell lines are presented in Supporting Figure S2.
Transfection with siRNA that mimics miR122 reduced luciferase
expression in HepG2 to below 10% while a negative control
siRNA only reduced the expression to 75%, giving further
evidence of miR122-specific silencing (Supporting Figure S3).
Suppression of luciferase activity was as expected not observed in
the neuroendocrine tumor cell lines BON, SH-SY-5Y, SK-N-
BE(2), Kelly (Figure 2A) while addition of siRNA mimicking
miR122 silenced transgene expression (Supporting Figure S3).
The potency of miR122-silencing was next examined in vivo.
miRNA are know to be evolutionary conserved across species and
H. sapiens and M. musculus miR122 precursors are clustering in the
same clade, which implicates recognition of similar target
sequences. Mice were injected intravenously (tail vein) with a
single dose of 5610
10 vp of the following vectors: Ad[CMV-Luc],
Ad[CgA-Luc] and Ad[CgA-Luc-miR122]. Six, 24 and 48 hours
after injection, luciferase activity was measured using the IVIS-100
system. In agreement with numerous other studies in mice, we
found that the liver is the primary target of Ad5-based vectors after
intravenous injection. Luciferase activity was observed in all mice
injected with Ad[CMV-Luc] and Ad[CgA-Luc] (Figure 2B and C)
already after 6 hours, while no luciferase activity was detected in
any of the mice injected with Ad[CgA-Luc-miR122], despite long
(10 minutes) exposure times (Figure 2D). Analysis after 6, 24 and
48 hours showed that the expression pattern does not change over
time (Figure 2B, C and D). The viral vector with the constitutively
active CMV promoter, Ad[CMV-Luc], resulted in significantly
higher luciferase expression (3-logs) in the mouse liver compare to
Ad[CgA-Luc] (Figure 2E).
Reduced E1A Protein Expression and Arrest of Viral
Replication Occurs Only in miR122-Expressing Hepatic
Cells
We next constructed two miR122-targeted oncolytic adenovi-
ruses, Ad[CgA-E1A-miR122] and Ad[CgA-E1A-miR12262],
where E1A gene expression is driven by the CgA promoter and
further controlled by six or twelve tandem repeats of miR122
Figure 1. Schematic illustration of recombinant adenoviruses.
Ad[CgA-Luc] and Ad[CgA-Luc-miR122] are E1-deleted Ad5-based
vectors with luciferase gene expression controlled by the human CgA
promoter. Ad[CgA-Luc-miR122] has six repeats of the miR122 target
sequence in the 39UTR of the luciferase gene. The oncolytic adenovirus
Ad[CgA-E1A], which has been previously described, has E1A expression
under control of the CgA promoter. Six and twelve repeats of the
miR122 target sequence were inserted in the 39UTR of the E1A gene in
Ad[CgA-E1A-miR122] and Ad[CgA-E1A-miR122x2], respectively.
doi:10.1371/journal.pone.0008916.g001
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normal hepatocytes with Ad[CgA-E1A] resulted in far lower E1A
protein expression than wild-type Ad5 (Ad5 wt) and E1A
expression was completely suppressed after transduction with
Ad[CgA-E1A-miR122] and Ad[CgA-E1A-miR12262] at MOI 1
(Figure 3A), indicating very efficient silencing. In comparison,
transduction of carcinoid cells yielded strong E1A protein
expression for all viruses (Figure 3A). When miR122-positive
HuH7.5 was transduced with Ad[CgA-E1A] weak E1A expression
was observed while E1A expression was completely abolished after
transduction with the miR122-detargeted viruses (Figure 3B). E1A
protein expression was not suppressed in miR122-negative HepG2
(Figure 3B). Moreover, in hepatocytes and HuH7.5, expression of
hexon protein was strongly reduced (Figure 3A, B), which indicates
that reduced E1A expression leads to production arrest of progeny
virions. The CgA promoter strongly supports E1A protein
expression, with efficiency comparable to the wild-type E1A
promoter of Ad5 wt, in neuroendocrine tumor cells and expression
was not altered by incorporation of miR122 target sequences in
the viral genome (Figure 3C).
Despite strong reduction of E1A expression, adenovirus may
still have the capacity to replicate [17]. We therefore evaluated
replication of the miR122-targeted oncolytic viruses by quantita-
Figure 2. Specific silencing of luciferase expression in liver cells
by miR122 in vitro and in vivo. (A) Freshly isolated primary cells and
cell lines were transduced with Ad[CgA-Luc] and Ad[CgA-Luc-miR122]
at MOI 10 and plated in 12-well plates. Cells were harvested after 48
hours and luciferase activity and protein concentration were deter-
mined. Luciferase activity was calculated as RLU/mg and expressed in
relation to Ad[CgA-Luc], which was set to 100% for each cell type. Data
are presented as the mean values of triplicates 6 std dev. (B-E) Balb/c
mice were injected i.v. with 5610
10vp of Ad[CMV-Luc] (B), Ad[CgA-Luc]
(C) or Ad[CgA-Luc-miR122] (D). Luciferase activity was monitored with
the IVIS-100 system 6, 24 and 48 hours after injection. (E) Comparison of
luciferase activity in mice liver after i.v. injection of Ad[CMV-Luc],
Ad[CgA-Luc] or Ad[CgA-Luc-miR122] (*** p,0.0001).
doi:10.1371/journal.pone.0008916.g002
Figure 3. miR122-mediated suppression of adenoviral protein
expression in hepatic cells. Primary cells (A), hepatoma cell lines (B)
and neuroendocrine tumor cell lines (C) were transduced with viruses at
MOI 1 (neuroblastoma cell lines at MOI 10). Total protein lysates were
prepared after 48 hours and 50 mg of samples were resolved by SDS-
PAGE. E1A was detected by Western blotting using an anti-E1A
antibody. The polyclonal anti-Ad serum (a-Prage) was used to detect
adenoviral capsid proteins. Hexon protein expression is shown to
visualize production of progeny virions.
doi:10.1371/journal.pone.0008916.g003
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(E4 orf1) copies at different time points after transduction.
Replication index was defined as the increase of copy number of
progeny viral DNA compared to the copy number obtained
2 hours after transduction (set to 1). Replication of Ad[CgA-E1A-
miR122] and Ad[CgA-E1A-miR12262] was completely attenu-
ated in HuH7.5 without production of progeny viral DNA, in
contrast to Ad[CgA-E1A] and Ad5 wt, which have replication
indexes of 330 and 7200, respectively, after 3 days (Figure 4A). As
expected, miR122-mediated inhibition of replication was not
observed for any of the viruses in HepG2 (Figure 4A). Importantly,
in carcinoid cells and in BON, the CgA promoter-driven oncolytic
viruses, either with or without miR122 target sequences, replicate
equally well and follow the pattern of Ad5 wt replication
(Figure 4A).
We next verified that Ad[CgA-E1A-miR122] and Ad[CgA-
E1A-miR12262] lyse BON cells to a similar degree as Ad[CgA-
E1A]. We found that all cells were killed when transduced at MOI
0.1 (Figure 4B). Ad[CgA-E1A] had weak activity and could kill
HuH7.5 cells to a certain degree (cell viability of 65%) when
transduced at MOI 1, while Ad[CgA-E1A-miR122] and Ad[CgA-
E1A-miR12262] had no effects (Figure 4B).
miR122-Detargeting of Adenovirus Leads to Reduced
Liver Toxicity
The Ad[CgA-E1A] and Ad[CgA-E1A-miR122] viruses were
next evaluated for liver activity in vivo. Viruses (5610
10 vp) were
injected intravenously (tail vein) on day 1, 4 and 7 and blood was
drawn and analyzed on day 9. We found that mice injected with
Ad[CgA-E1A] had significantly elevated serum levels of ALT,
which is indicative of liver toxicity, while no mice injected with
Ad[CgA-E1A-miR122] had elevated ALT levels (Figure 5).
Combination of Transcriptional (Promoter) and Post-
Transcriptional (miRT) Regulation Yields the Most Specific
Viruses with the Lowest Activity in Hepatic Cells
We finally wanted to extensively assess the benefit of having
both promoter and miRT-controlled E1A expression for reduced
activity in hepatic cells. We therefore compared the silencing effect
of Ad[CgA-E1A-miR122] with two other miR122-detargeted
adenoviruses, one where E1A is controlled by the wild-type E1A
promoter Ad[E1Ap-E1A-miR122] and one where it is controlled
by the prostate cell-specific iPPT promoter, Ad[iPPT-E1A-
miR122]. To evaluate the effect of each modification replication
efficacies and lytic abilities were also compared with Ad[E1Ap-
E1A], Ad[CgA-E1A] and Ad[iPPT-E1A] as well as wild-type Ad5.
MiR122-positive hepatic cells (HuH7.5) and miR122-negative
carcinoid cells (BON) were transduced at MOI 1 and the gene
copy numbers of E4 orf1 were measured by QRT-PCR after two
days. The copy numbers were expressed in relation to the copy
numbers obtained 2 hours after transduction for the same virus
(set to 1), as a measurement of virus replication. The wild-type Ad5
virus replicated best in both cell lines, while the E1B-deleted
Ad[E1Ap-E1A] (otherwise wild-type Ad5) virus yielded approxi-
mately 90% E4 orf1 gene copy numbers compared to Ad5 wild
type both in HuH7.5 and BON, showing that E1B deletion had
only minor effects on replication in these cell lines (Figure 6A and
6B). The single targeted Ad[E1Ap-E1A-miR122] and Ad[CgA-
E1A] viruses yielded approximately 7-fold and 5-fold less genome
copies than Ad5 wt and Ad[E1Ap-E1A], respectively in HuH7.5
(Figure 6A). On the other hand, transduction with the double-
targeted Ad[CgA-E1A-miR122] virus yielded 100-fold and 70-fold
less genome copies than Ad5 wt and Ad[E1Ap-E1A], respectively,
indicating an additive effect of combining promoter targeting with
miRT detargeting. In BON cells Ad[E1Ap-E1A], Ad[E1Ap-E1A-
miR122], Ad[CgA-E1A] and Ad[CgA-E1A-miR122] yielded
similar levels of genome copies (Figure 6B), showing that
introduction of miR122 target sequence in the viral genomes
Figure 4. Replication arrest and reduced cytolytic activity in
hepatic cells for adenoviruses carrying miR122 target sites. (A)
Cells were transduced with viruses at MOI 1 (neuroblastoma cell lines
at MOI 10). Viral DNA was isolated 2 hours, 1, 2 and 3 days after
transduction. QRT-PCR was performed to measure E4 orf1 gene copies.
Fold increase of viral genome copies is expressed in relation to genome
copies detected after 2 hours (set to 1). (B) HuH7.5 and BON cells were
transduced with viruses at various MOIs (0.001-1). Cell viability was
examined 6 days after transduction and expressed in relation to the
viability of untransduced cells.
doi:10.1371/journal.pone.0008916.g004
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Transduction of HuH7.5 and BON with the prostate cell-specific
Ad[iPPT-E1A] and Ad[iPPT-E1A-miR122] viruses did not result
in significant numbers of genome copies after two days, indicating
strongly abolished replication capacity of these viruses in hepatic
cells (Figure 6A and 6B). This shows that a tissue-specific promoter
alone, if highly specific, can almost completely attenuate virus
replication in non-permissive cells.
Next, we wanted to examine whether suppressed replication
correlates with reduced cell-killing efficacy. An MTS cell viability
assay was carried out using HuH7.5 and BON cells transduced
with the same set of viruses at MOIs ranging from 0.0001-100. As
expected, the Ad5 wt virus was the most efficient in killing HuH7.5
and BON cells, while AdMock did not show lytic ability even at
MOI 100 (Figure 7A and 7B). Transduction of HuH7.5 with
Ad[CgA-E1A-miR122] at MOI 1 did not reduce cell viability,
while Ad5 wt, Ad[E1Ap-E1A], Ad[E1Ap-E1AmiR122] and
Ad[CgA-E1A] transduction results in killing of 95%, 85%, 80%
and 45% of the cells, respectively (Figure 7A). Ad[CgA-E1A-
miR122] and Ad[iPPT-E1A-miR122] start to yield reduced cell
viability at MOI 10 and 100, respectively, indicating that at those
MOIs the viral E1A mRNA molecules may outnumber cellular
miR122 molecules in HuH7.5. Transduction of BON cells at an
MOI of 1 results in at least 75% cell killing, for all oncolytic viruses
except Ad[iPPT-E1A] and Ad[iPPT-E1A-miR122] (Figure 7B).
Our data show that while introduction of a miR122 target
sequence in the 39UTR of the E1A gene leads to reduced killing of
hepatic cells, it does not affect the desired killing of miR122-
negative target cells.
Discussion
MicroRNA targeting (miRT) has been used to control transgene
expression from viral vectors and viral genes important for
replication of oncolytic viruses in tissue-specific manners
[6,8,9,10,18]. An extensive discussion on how to design miRNA
target sequences for viral vectors can be found as supporting
information Text S1 to this manuscript (miRNA target design). If
miRT sequences are placed in a small single-stranded positive-sense
(+) RNA genome such as picornaviruses, they become part of the
single viral mRNA [8]. miRNA-mediated silencing of adenovirus
replication is somewhat more complex due to the large number of
transcripts. However, in order to control adenovirus replication by
miRNAs,theE1Ageneisagoodcandidate,since itencodesproteins
that trigger viral replication and modulate cellular metabolism to
make the cell more susceptible to replication. Low levels of E1A
protein can be sufficient in supporting adenoviral replication [17]. It
may therefore be attractive to introduce miRT sequences in other
adenoviral genes, such as E2 or E4, in addition to E1A, in order to
further restrict adenoviral replication in the liver and other potential
off-target cell types, such as Kupffer cells, monocytes and other
hematopoetic cells. Targeting more than one adenoviral gene
essential for replication and employing various tissue-specific
miRNAs may also protect from loss of activity due to intrinsic
miRNA silencing through mutation or deletion of miRT sequences.
In a previous paper, we used the CgA promoter to control E1A
expression with the intention to develop an Ad5-based oncolytic
adenovirus, Ad[CgA-E1A], for carcinoid therapy [11]. Since
midgut carcinoids metastasize to the liver, intrahepatic or
intratumoral virus injections would be the most likely route of
delivery for treatment of liver metastases. It is therefore crucial that
normal liver cells do not support virus replication. We found that
CgA promoter-controlled E1A expression results in strong
attenuation of E1A protein expression in hepatocytes but that it
does not completely abolish expression [11]. In order to further
restrict adenoviral replication in hepatocytes we set out to regulate
E1A gene expression by the liver-specific miR122. Combined
regulation of the E1A gene by the CgA promoter and miR122
target sequences, acts together and can efficiently repress E1A
protein expression in cells expressing miR122. It leads to abolished
adenoviral replication and reduced cytolytic activity. Moreover,
our miR122-targeted oncolytic adenoviruses fully retain replica-
Figure 5. Lack of hepatotoxicity in mice injected with Ad[CgA-
E1A-miR122]. Balb/c mice received three intravenous injections with
5610
10vp of Ad[CgA-E1A] or Ad[CgA-E1A-miR122] on days 1, 4 and 7.
Blood was collected on day 9 and plasma was obtained by incubation
blood with heparin (20 U per ml of blood) and used for the
measurement of ALT levels (*p=0,0011).
doi:10.1371/journal.pone.0008916.g005
Figure 6. Greater replication arrest by double-targeted than
single-targeted adenovirus in hepatic cells. HuH7.5 (A) and BON
(B) were transduced at MOI 1. Viral DNA was isolated 2 hours and
2 days after transduction. QRT-PCR was performed to measure E4 orf1
copies. Fold increase of viral genome copies after 2 days is expressed in
relation to genome copies detected after 2 hours (set to 1). Data are
presented as the mean of triplicates 6 std dev.
doi:10.1371/journal.pone.0008916.g006
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There was no difference between the two miRT-modified viruses
in terms of replication in hepatocytes, indicating that six copies of
miR122 target sequences are sufficient to completely attenuate
genes controlled by the CgA promoter. In a recent paper Ylosmaki
et al, incorporated miR122 target sequences in the 39UTR of E1A
of an Ad5 virus, which retained the wild-type E1A promoter [10].
They observed decreased E1A protein levels in the hepatoma cell
line HuH7 when the cells were transduced at a very low MOI of
0.05. However, this was not sufficient to suppress replication. They
managed to improve miR122-responsivness of their recombinant
adenovirus by modifying the 59UTR of the E1A gene. However, it
resulted in uniform and unspecific reduction of E1A protein levels
in all tested cells. Cawood et al also kept the wild-type E1A
promoter and used four miR122 target sequences in the 39UTR of
E1A to reduce Ad5 activity in hepatic cells [9]. They did not
report whether insertion of miR122 target sequences was enough
to attenuate virus replication in HuH7. Our data demonstrate
partial attenuation of replication for Ad[E1Ap-E1A-miR122]
(wild-type Ad5 E1A promoter) in HuH7.5, especially at MOI
10. However, complete replication arrest can be obtained as
demonstrated by our double-targeted Ad[CgA-E1A-miR122]
virus in HuH7.5 and also in normal human hepatocytes. Cawood
et al reported reduced liver toxicity in mice after one intravenous
injection of 5610
10vp for their miR122-detargeted virus compared
to wild-type Ad5 [9]. We had to inject 5610
10vp of Ad[CgA-E1A]
at three occasions before we started to see elevated ALT levels and
with the Ad[CgA-E1A-miR122] virus we did not see elevated
ALT levels even after three injections.
Furthermore, we made side-by-side comparisons of three
miR122-detargeted viruses; one with the wild-type E1A promoter,
one with the neuroendocrine cell-selective CgA promoter and one
with the prostate cell-specific iPPT promoter. We found that a
combination of transcriptional (promoter) and post-transcriptional
(miRT) targeting is clearly advantageous in terms of attenuation of
virus replication in hepatic cells. Our data suggests that in order to
reduce virus replication in hepatic cells, miR122-detargeting alone
is effective but not efficient enough to completely attenuate virus
replication. It is better to combine it with a promoter that has wild
type-like activity in tumor cells but reduced activity in hepatic cells.
The combination of transcriptional and post-transcriptional
regulation to control virus replication yields a possibility to use
higher doses of adenoviruses for more efficient and specific tumor
treatment without inducing dose-related liver toxicity. In conclu-
sion, the double-targeted Ad[CgA-E1A-miR122] virus has
potential for the treatment of neuroendocrine tumors that
metastasize to the liver.
Materials and Methods
Ethics Statement
Carcinoid specimens were obtained from patients who under-
went liver surgery to remove midgut carcinoid metastases, while
wedge biopsies of normal liver were taken from patients who
underwent liver surgery for different reasons than carcinoid tumor.
A written consent statement was obtained from each patient. All
experimental procedures were approved by the Regional Ethical
Committee at the Uppsala University Hospital (Regionala
etikpro ¨vningsna ¨mnden i Uppsala), with reference numbers
2004:M-223 (Hepatocytes) and 2009/152 (Carcinoids). The
Uppsala Animal Ethical Committee (Uppsala Djurfo ¨rso ¨ksetiska
na ¨mnd, Ref. no. C52/7) has approved all experimental proce-
dures.
Cell Lines
The human endocrine pancreatic tumor cell line BON (a kind
gift from Prof J.C. Thompson, Galveston, TX) was cultured in
DMEM with Glutamax-I and F12 Nutrient Mixture (Kaighn9s
modification) at a ratio of 1:1, supplemented with 10% fetal bovine
serum (FBS), 1 mM sodium puruvate and 1% penicillin/
streptomycin (PEST). The human neuroblastoma cell lines SH-
SY-5Y and SK-N-BE(2) (Dr F. Hedborg, Uppsala University,
Uppsala, Sweden) were cultured in MEM with Earl9s salt and L-
glutamine, supplemented with 10% FBS, 1 mM sodium puruvate,
1% PEST. The neuroblastoma cell line Kelly was cultured in
RPMI-1640 medium, supplemented with 10% FBS, 1 mM
sodium puruvate, 1% PEST. The human hepatoma cell lines
HuH7.5 (Apath, L.L.C., St.Louis, MO) and HepG2 (Prof N.
Maitland, University of York, York, UK) were cultured in DMEM
with Glutamax-I, supplemented with 10% FBS, 1 mM sodium
puruvate, 3.2 mM L-glutamine, 1% Non-Essential Amino Acids,
1% PEST. The 911 (Crucell, Leiden, The Netherlands) and lung
Figure 7. Stronger reduction of cytolytic ability in hepatic cells
by double-targeted than single-targeted adenovirus. HuH7.5 (A)
and BON (B) were transduced at various MOIs (0.0001-100). Cell viability
was examined 6 (HuH7.5) and 4 (BON) days after transduction. Cell
viability values were expressed in relation to the viability of
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production, were cultured in DMEM supplemented with 10%
FBS, 1 mM sodium pyruvate, 1% PEST. All cell culture reagents
were from Invitrogen (Carlsbad, CA).
Isolation and Culture of Primary Cells
Isolation and culture conditions of normal hepatocytes have
been described earlier [11]. Carcinoid tumor specimens were
placed in ice-cold rinse buffer [0.1% BSA, 2.5 mM Hepes, DNaseI
(0.05 mg/ml), NaCl (800 mg/L), KCl (35 mg/L), MgSO4x7H2O
(16 mg/L), CaCl2xH2O (18 mg/L)]. Cold ischemic time was 30–
60 minutes. Tumor samples were transferred to a sterile Petri-dish
and cut into small pieces with a scalpel and placed in digestion
buffer [Ham’s F-10, Collagenase (2 mg/ml), DNAse I (0.05 mg/
ml), 1.5% BSA, 1.25 mM CaCl2] for 40 min at 37uC, while
shaking. The digested tumor specimens were filtered through a
sterile metal grid (mesh size 440 mm) with rinse buffer, collected
and centrifuged (3006g, 10 min, RT). The supernatant was
removed and cells were resuspended in 0.5 ml EGTA buffer
[NaCl (8.3 g/L), KCl (0.5 g/L), 25 mM Hepes, EGTA (0.38 g/
L)] and mixed with 5 ml rinse buffer. Five ml 60% Percoll solution
(GE Healthcare Life Sciences, Uppsala, Sweden) was added to the
bottom of the tube, followed by centrifugation (3006g, 10 min,
RT). The middle phase was transferred into a new tube followed
by addition of 5 ml rinse buffer. Five ml 25% Percoll solution was
added to the bottom of the tube and the cells were centrifuged
(3006g, 10 min, RT). The supernatant was removed and cells
were resuspended in HITES medium [RPMI-1640, supplemented
with 1% ITS-G (Invitrogen), estradiol (0.24 mg/ml), hydrocortisol
(0.36 mg/ml), 5% FBS (Invitrogen), 1% L-glutamine (Invitrogen),
1% PEST (Invitrogen)]. Cells were plated in T-75 cell-bind flasks
(Corning, Lowell, MA). The carcinoid cells were rigidly flushed
and collected the following day, leaving a small number of
fibroblast adherent in the flasks. The carcinoids cells were
trypsinized and plated in fresh T-75 cell-bind flasks overnight.
Cells were used for experiments the day after, i.e., 48 hours after
surgery. All chemicals were from Sigma-Aldrich (St. Louis, MO),
except when stated differently.
Recombinant Adenoviruses
The recombinant adenoviruses in this study are E1B-deleted
and based on human serotype 5 (Ad5) and constructed using
AdEasy technology. The Ad5 backbone vector pAdEasy(E3) and
the transfer vector pShuttle-i/CgA-E1A, which were used for
construction of Ad[CgA-E1A] have been described earlier [11,19]
and so has the constructions of AdMock and Ad[CMV-Luc] [20]
and the prostate-specific Ad[iPPT-E1A] [19]. The Ad5 E1A gene
was PCR amplified from wild-type Ad5 DNA using the following
primers: E1A.for 59-AAG CTT CTC TTG AGT GCC AGC
GAG TA-39 (HindIII site underlined); E1A.rev: 59-GTC GAC
CCA TTT AAC ACG CCA TGC AAG T-39 (SalI site
underlined), followed by TOPO TA-cloning into pCR2.1
(Invitrogen), sequencing and HindIII/SalI subcloning into pShut-
tle(i/CgA-E1A) where it replaced the old SalI/SalI-cloned E1A
sequence. A synthetic dsDNA sequence containing six tandem
repeats, complementary to the mature hsa-miR-122 target
sequences (http://microrna.sanger.ac.uk/) with six nucleotide
spacers between each repeat, and flanked by XbaI sites and an
upstream HpaI site and a downstream SmaI site was purchased in
a pGA4 plasmid (GeneArt, Regensburg, Germany). The miR122
target sequence was excised from the pGA4 plasmid with HpaI
and SmaI and blunt-end cloned into the unique HpaI site in the
39UTR region of E1A of pShuttle(i/CgA-E1A), located approx-
imately 30 bp downstream of the E1A stop codon and 40 bp
upstream of the E1A polyadenylation signal. We sequenced two
clones with the insert in the correct orientation, one with six
miR122 target sequences: pShuttle(i/CgA-E1A-miR122) and one
with 12 tandem repeats of the miR122 target sequence:
pShuttle(i/CgA-E1A-miR12262). Furthermore, the miR122 tar-
get sequence was excised from the pGA4 plasmid and cloned into
the unique XbaI site directly downstream of the luciferase stop
codon in pShuttle vectors. The E1A promoter was amplified from
wild-type Ad5 DNA (ATCC) using the following primers: E1A-
prom.for 59-GGT ACC GGG CCG CGG GGA CTT TG-39
(KpnI site underlined); E1Aprom.rev: 59-AAG CTT TGG CCT
CTT GAG GAA CTC AC-39 (HindIII site underlined) followed
by TOPO TA-cloning into pCR2.1 (Invitrogen) and sequencing.
pShuttle(E1Ap-E1A) and pShuttle(E1Ap-E1A-miR122) were cre-
ated by replacing the iCgA promoter with the E1A promoter using
KpnI and HindIII. The pShuttle(i/PPT-Luc) plasmid [19] was
digested with XbaI (unique site directly downstream of the
luciferase stop codon), made blunt end by Klenow fragment,
followed by insertion of the HpaI/SmaI-excised miR122 target
sequences (six copies) to construct pShuttle(i/PPT-Luc-miR122).
The PPT promoter was replaced with the CgA promoter both in
pShuttle(i/PPT-Luc) and pShuttle(i/PPT-Luc-miR122) using
NotI and HindIII to construct pShuttle(i/CgA-Luc) and pShut-
tle(i/CgA-Luc-miR122). Plasmids with full length E1B-deleted
adenovirus genomes: Ad[CgA-Luc], Ad[CgA-Luc-miR122], Ad[-
CgA-E1A], Ad[CgA-E1A-miR122], Ad[CgA-E1A-miR122x2],
Ad[E1Ap-E1A], Ad[E1Ap-E1A-miR122] and Ad[iPPT-E1A-
miR122] were obtained through homologous recombination in
BJ5183 between pAdEasy(E3) [19] and described pShuttle
plasmids. Wild-type Ad5 was purchased from ATCC and
amplified in A549 cells while recombinant viruses were produced
in 911 cells. Viruses were purified by CsCl banding and dialyzed
against a buffer containing 10 mmol/L Tris-HCL (pH 8.0),
2 mmol/L MgCl2 and 4% sucrose. Virus titers were determined
by a fluorescence-forming unit (FFU) assay and viral particle (vp)
concentrations were determined by spectrophotometer using
standard protocols. The recombinant viruses and wild-type Ad5
(Ad5wt) were stored in aliquots in 280uC.
Analysis of Endogenous miR122 Expression
Total RNA was extracted from cell lines and freshly isolated
carcinoid cells by using Trizol (Invitrogen). Total RNA from
normal human liver and Balb/c mouse liver were obtained from
15–20 cryosections (20 mm), which were added to 600 ml of the
RLT lysis buffer from the RNeasy Mini Kit (Qiagen, Hilden,
Germany). Reverse transcriptase reactions were performed using
1 mg of total RNA of each sample and the QuantiMir RT Kit
(System Biosciences, Mountain View, CA), according to the
manufacturer’s instructions. cDNA (diluted 1:100) was used for
QRT-PCR together with the miR122.For primer 59-TGG AGT
GTG ACA ATG GTG TTT G-39 and the 39 Universal Primer
provided by the QuantiMir RT Kit. Human and mouse U6
snRNA were amplified with primers provided from the QuantiMir
RT Kit. The PCR products were measured by iCycler IQ real-
time detection system using iQ SYBRGreen supermix (Bio-Rad,
Hercules, CA). Data were evaluated using the 2
2DDCT method
[21,22]. The miR122 expression levels were normalized against
the U6 snRNA transcript levels.
Luciferase Assay
Cells were transduced in suspension with Ad[CgA-Luc] and
Ad[CgA-Luc-miR122] at a multiplicity of infection (MOI) of 10
FFU/cell. Two hours after transduction cells were plated in 12-
well plates. Some cells were subsequently transfected with 10 nM
Double-Detargeted Adenovirus
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(miRIDIAN Mimic, Thermo Scientific Dharmacon, Chicago,
IL) or non-related siRNA (miRIDIAN Negative Control) using
INTERFERin (Polyplus Transfection, New York, NY) according
to the manufacturer’s protocol. Total lysates were obtained after
48 hours and luciferase assays were performed as described earlier
[19]. Luciferase activity was measured and calculated as raw light
unit (RLU) per mg of protein and expressed in relation to
Ad[CgA-Luc], which for each cell type was set to 100%.
Animal Studies
Female Balb/c mice, 6–8 weeks of age (B&K Universal,
Sollentuna, Sweden), were injected intravenously (tail vein) with
5610
10vp of Ad[CMV-Luc], Ad[CgA-Luc] or Ad[CgA-Luc-
miR122] in 200 ml of buffer (10 mM Tris-HCL (pH 8.0), 2 mM
MgCl2 and 4% sucrose). Luciferase activity was measured 6, 24
and 48 hours after injection as described before [11]. Counter
regions of interest (ROIs) were created and signals were quantified
as photons per second per square centimeter per steradian. For
liver toxicology studies, female Balb/c mice were injected in the
tail vein on days 1, 4 and 7 with 5610
10vp of Ad[CgA-E1A] or
Ad[CgA-E1A-miR122]. On day 9, blood was collected by cardiac
puncture. Plasma was obtained by incubation of 600 ml of blood
with 12 U of heparin for 15 min at RT followed by centrifugation
for 20 min at 4uC, 30006g. Alanine aminotransferase (ALT) levels
were measured at the Clinical Chemistry Lab (University Animal
Hospital, Uppsala, Sweden).
Western Blot
Cells cultured on six-well plates were transduced at 60–80%
confluency with viruses at MOIs of 1 or 10 FFU/cell. Cells were
harvested 48 hours later and total protein extracts were prepared
as described earlier [20]. E1A protein expression was determined
as described earlier [11] using 50 mg of total lysates. The
membranes where then stripped, washed and incubated with a-
Prage [23], which is rabbit serum against adenoviral capsid
proteins (a kind gift from Dr G. Akusja ¨rvi, Uppsala University,
Uppsala, Sweden).
Replication Assay
Cells were transduced in suspension with viruses at 1 or 10
FFU/cell. Two hours after transduction cells were washed and
plated in 24-well plates (2.5610
5 cells per well). Cell were
harvested directly (day 0) and 1, 2, 3 days after transduction,
followed by viral DNA isolation using the High Pure Viral Nucleic
Acid Kit (Roche Applied Sciences, Mannheim, Germany)
according to the manufacturer’s protocol. Viral replication was
detected by QRT-PCR with primers for the adenoviral E4 orf1
transcript: E4.For 59-CAT CAG GTT GAT TCA CAT CGG-39
and E4.Rev 59-AAG CGC TGT ATG TTG TTC TG-39. Gene-
specific PCR products were measured by iCycler IQ real-time
detection system (Bio-Rad, Hercules, CA) using iQ SYBR Green
supermix (Bio-Rad). The data were evaluated using the 2
2DDCT
method [21,22] using the DNA level of E4 gene from day 0 from
each sample for normalization.
Cell Viability Assay
Cells were transduced in suspension with viruses at MOIs of
0.0001-100, FFU/cell. Two hours after transduction, the cells
were plated in 96-well plates (1610
4 cells per well). Cell viability
was analyzed 4 or 6 or after transduction using the MTS cell titer
96 aqueous one solution cell proliferation assay (Promega,
Madison, WI) according to the manufacturer’s instructions.
Statistical Analysis
Significance was evaluated using one-way ANOVA (GraphPad
Software, San Diego, CA) and denoted in the graphs as * p,0.01
and *** p, 0.0001.
Supporting Information
Text S1 miRNA target design
Found at: doi:10.1371/journal.pone.0008916.s001 (0.04 MB
DOC)
Figure S1 Analysis of endogenous miR122 expression. cDNAs
were synthesized using 1 mg of total RNA from normal human
liver, Balb/c mice liver and a panel of cell lines using the
QuantiMir kit. QRT-PCR was performed to detect miR122
transcripts and Ct values were calculated from triplicate samples,
data were evaluated using the 2
2DDCT method and expressed in
relation to the level of snRNA U6.
Found at: doi:10.1371/journal.pone.0008916.s002 (0.01 MB
PDF)
Figure S2 miR122-specific silencing of luciferase expression.
Freshly isolated primary cells and cell lines were transduced with
Ad[CgA-Luc] and Ad[CgA-Luc-miR122] at MOI 10 and plated
in 12-well plates. Cells were harvested after 48 hours and luciferase
activity and protein concentration were determined. Luciferase
activity was calculated as RLU/mg. Data are presented as the
mean values of triplicates 6 SD.
Found at: doi:10.1371/journal.pone.0008916.s003 (0.01 MB
PDF)
Figure S3 Specific silencing of luciferase transgene by mimic
siRNA. Cells were transduced with Ad[CgA-Luc] and Ad[CgA-
Luc-miR122] at MOI 10 and plated in 12-well plates. In addition,
cells were co-transfected with 10 nM of mimic siRNA (acting as
hsa-miR-122) or negative control siRNA (non-related). Cells were
harvested after 48 hours and luciferase assay and protein
concentration measurements were performed. Luciferase activity
was calculated as RLU/mg and expressed in relation to Ad[CgA-
Luc] which was set to 100%, for each cell type. Transduction with
Ad[CgA-Luc] and co-transfection with negative or mimic siRNA,
yielded no difference in luciferase activity compared to Ad[CgA-
Luc] alone for any of the cells (data not shown).
Found at: doi:10.1371/journal.pone.0008916.s004 (0.06 MB
PDF)
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